The BT Test™ and Early Breast Cancer
Detection
When detected and treated in its early stages, breast cancer carries a 96-percent survival rate - yet the disease kills more women than any other form of cancer. The BT Test is designed to complement other testing methods to aid doctors in more accurately diagnosing breast cancer in its early stages, when life-saving treatment is most effective.
Created to work in conjunction with annual mammograms and other trusted
breast cancer detection methods, the BT Test is an innovative blood test that ensures patients receive the most thorough diagnosis possible.
While mammography continues to be a tried and true method of breast cancer detection, the procedure has several limitations that signal a need for an early breast cancer test that can increase accuracy in diagnosis, is cost-effective and is easier to administer than existing diagnostic procedures. In fact, mammograms have the following limitations:
- A mammogram’s ability to detect cancer accurately is dependent on which radiologist reads it, leading to highly subjective results, according to a Group Health study published in the Journal of the National Cancer Institute
- 20 percent of mammograms result in false negatives, leaving breast cancer undetected
- Seven percent result in false positives, leading to unneeded biopsies
One in eight women will be diagnosed with breast cancer in her lifetime, and mammography alone does not do enough. Learn more about this serious disease and the medical research behind the BT Test below, and look for more information on receiving this potentially life-saving test soon.
About Breast Cancer
BT Test Research